NASDAQ:CSIICardiovascular Systems Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cardiovascular Systems Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $30.99 -1.23 (-3.82 %) (As of 07/6/2020 04:00 PM ET) Add Compare Share Today's Range$30.92Now: $30.99▼$32.7550-Day Range$30.30MA: $35.46▼$41.5052-Week Range$26.00Now: $30.99▼$55.22Volume308,341 shsAverage Volume336,293 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/ABeta1.47 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingCardiovascular Systems has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.14, Cardiovascular Systems has a potential upside of 55.3% from its current price of $30.99.Amount of Analyst CoverageCardiovascular Systems has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesCardiovascular Systems has received 396 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCardiovascular Systems has received 367 “underperform” votes. (Add your “underperform” vote.)Community SentimentCardiovascular Systems has received 51.90% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote “Outperform” if you believe CSII will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCardiovascular Systems does not currently pay a dividend.Dividend GrowthCardiovascular Systems does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiovascular Systems insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Cardiovascular Systems is held by insiders.Percentage Held by Institutions92.81% of the stock of Cardiovascular Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cardiovascular Systems are expected to grow in the coming year, from ($0.81) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiovascular Systems is -99.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiovascular Systems is -99.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiovascular Systems has a P/B Ratio of 7.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:CSII Previous Symbol CUSIP14161910 CIK1180145 Webwww.csi360.com Phone651-259-1600Debt Debt-to-Equity Ratio0.15 Current Ratio3.29 Quick Ratio2.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$248.02 million Price / Sales4.41 Cash Flow$0.09 per share Price / Cash Flow357.81 Book Value$4.25 per share Price / Book7.29Profitability EPS (Most Recent Fiscal Year)($0.01) Net Income$-250,000.00 Net Margins-4.04% Return on Equity-7.36% Return on Assets-4.82%Miscellaneous Employees652 Outstanding Shares35,274,000Market Cap$1.09 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:CSII Rates by TradingView Receive CSII News and Ratings via Email Sign-up to receive the latest news and ratings for CSII and its competitors with MarketBeat's FREE daily newsletter. Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions How has Cardiovascular Systems' stock been impacted by COVID-19 (Coronavirus)? Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CSII stock has decreased by 14.7% and is now trading at $30.99. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cardiovascular Systems? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cardiovascular Systems. When is Cardiovascular Systems' next earnings date? Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cardiovascular Systems. How were Cardiovascular Systems' earnings last quarter? Cardiovascular Systems Inc (NASDAQ:CSII) released its quarterly earnings data on Tuesday, May, 5th. The medical device company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The medical device company earned $61.18 million during the quarter, compared to the consensus estimate of $64 million. Cardiovascular Systems had a negative return on equity of 7.36% and a negative net margin of 4.04%. View Cardiovascular Systems' earnings history. What price target have analysts set for CSII? 7 brokerages have issued 12 month price objectives for Cardiovascular Systems' shares. Their forecasts range from $44.00 to $58.00. On average, they anticipate Cardiovascular Systems' stock price to reach $48.14 in the next twelve months. This suggests a possible upside of 55.3% from the stock's current price. View analysts' price targets for Cardiovascular Systems. Has Cardiovascular Systems been receiving favorable news coverage? Media stories about CSII stock have been trending negative on Monday, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiovascular Systems earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Cardiovascular Systems. Are investors shorting Cardiovascular Systems? Cardiovascular Systems saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,130,000 shares, a decrease of 11.7% from the May 31st total of 1,280,000 shares. Based on an average daily trading volume, of 292,000 shares, the days-to-cover ratio is currently 3.9 days. Approximately 3.3% of the company's stock are sold short. View Cardiovascular Systems' Current Options Chain. Who are some of Cardiovascular Systems' key competitors? Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Insulet (PODD). View all competitors. What other stocks do shareholders of Cardiovascular Systems own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include AbbVie (ABBV), Gilead Sciences (GILD), Netflix (NFLX), Adobe (ADBE), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Medtronic (MDT), Pfizer (PFE), Procter & Gamble (PG) and Target (TGT). Who are Cardiovascular Systems' key executives? Cardiovascular Systems' management team includes the following people: Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 59)Mr. Jeffrey S. Points, Chief Financial Officer (Age 42)Ms. Rhonda J. Robb, Chief Operating Officer (Age 51)Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 47)Ms. Laura J. Gillund, Chief Talent Officer (Age 58) What is Cardiovascular Systems' stock symbol? Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII." How do I buy shares of Cardiovascular Systems? Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cardiovascular Systems' stock price today? One share of CSII stock can currently be purchased for approximately $30.99. How big of a company is Cardiovascular Systems? Cardiovascular Systems has a market capitalization of $1.09 billion and generates $248.02 million in revenue each year. The medical device company earns $-250,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe. What is Cardiovascular Systems' official website? The official website for Cardiovascular Systems is www.csi360.com. How can I contact Cardiovascular Systems? Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
